BetterLife Pharma Appoints Former NHL Player Daniel Carcillo as Corporate Advisor for TBI Treatment Development

BetterLife Pharma Inc. has announced the appointment of Daniel Carcillo as corporate advisor to advance the company's development of BETR-001, a proprietary non-hallucinogenic derivative of LSD focused on treating traumatic brain injury, cluster headache, and migraine. Carcillo brings unique firsthand experience to this role, having been forced to retire from professional hockey at age 30 due to Post Concussion Syndrome after suffering seven concussions during his NHL career with the Chicago Blackhawks, where he won two Stanley Cups.

Following his retirement in 2015, Carcillo created a non-profit organization assisting former NHL players suffering from post-concussion syndrome and mental health issues. He has become a well-known speaker and advocate for TBI survivors and people dealing with mental health challenges. Carcillo previously founded and served as CEO of Wesana Health, a life sciences company that leveraged psilocybin-based medicine to treat traumatic brain injuries. His appointment represents a strategic move for BetterLife as the company advances its neurological treatment portfolio.

Carcillo stated that joining BetterLife feels like the natural next step in his mission to help concussion survivors, noting they are advancing a medicine that carries the promise of psychedelic healing without the regulatory barriers while maintaining serotonergic benefits. He emphasized his personal experience with brain trauma and the importance of giving athletes, veterans, and anyone living with the invisible weight of concussion a real chance to heal and reclaim their lives. Dr. Ahmad Doroudian, CEO of BetterLife, expressed excitement about Carcillo joining the advisory group, highlighting that his firsthand experience with TBI and passion for advancing treatments will provide invaluable guidance for the company's development efforts.

BetterLife's BETR-001 is currently in preclinical and IND-enabling studies as a non-hallucinogenic and non-controlled LSD derivative. The treatment's unique characteristic of being unregulated allows for potential self-administration, while the company's synthesis patent eliminates regulatory hurdles. BetterLife's pending patent for composition and method of use covers treatment of various neurological disorders until approximately 2042. The company also owns a drug candidate for viral infections treatment and is seeking strategic alternatives for its further development. For additional information about the company's research and development initiatives, visit https://www.blifepharma.com.